FMP
COMPASS Pathways plc
CMPS
NASDAQ
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
8.34 USD
-0.14 (-1.68%)
About
ceo
Mr. Kabir Kumar Nath M.A., M.B.A.
sector
Healthcare
industry
Medical - Care Facilities
website
https://compasspathways.com
exchange
NASDAQ
Description
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
CIK
0001816590
ISIN
US20451W1018
CUSIP
20451W101
Address
33 Broadwick Street
Phone
44 64 6905 3974
Country
GB
Employee
186
IPO Date
Sep 18, 2020
Key Executives
